Education
About Us
Working with TipRanks
Follow Us
Ryvu Therapeutics SA (PL:RVU)
:RVU
RVU Stock Chart & Stats
zł27.65
--
Market closed
zł27.65
--
Day’s Range― - ―
52-Week Rangezł19.28 - zł36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)26.70K
Market Cap
zł538.70M
Enterprise Valuezł527.13M
Total Cash (Recent Filing)zł130.69M
Total Debt (Recent Filing)zł70.54M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,120,148
10 Day Avg. Volume24,770
30 Day Avg. Volume26,695
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)6.19
Price to Sales (P/S)11.42
P/FCF Ratio-6.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.98
Revenue Forecast (FY)zł285.35M
RVU FAQ
What was Ryvu Therapeutics SA’s price range in the past 12 months?
Ryvu Therapeutics SA lowest stock price was zł19.28 and its highest was zł36.00 in the past 12 months.
What is Ryvu Therapeutics SA’s market cap?
Ryvu Therapeutics SA’s market cap is zł538.70M.
When is Ryvu Therapeutics SA’s upcoming earnings report date?
Ryvu Therapeutics SA’s upcoming earnings report date is May 20, 2026 which is in 62 days.
How were Ryvu Therapeutics SA’s earnings last quarter?
Currently, no data Available
Is Ryvu Therapeutics SA overvalued?
According to Wall Street analysts Ryvu Therapeutics SA’s price is currently Overvalued.
Does Ryvu Therapeutics SA pay dividends?
Ryvu Therapeutics SA does not currently pay dividends.
What is Ryvu Therapeutics SA’s EPS estimate?
Ryvu Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ryvu Therapeutics SA have?
Ryvu Therapeutics SA has 23,120,148 shares outstanding.
What happened to Ryvu Therapeutics SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ryvu Therapeutics SA?
Currently, no hedge funds are holding shares in PL:RVU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Technical Analysis
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
Captor Therapeutics SA
―
OncoArendi Therapeutics SA
―
Selvita SA
―
Mabion SA
―